title: The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease.
authors.affiliation: a Department of Medicine , University of Göteborg, Sahlgrenska Academy , Göteborg , Sweden ;
authors.forename: Thomas
authors.initials: T
authors.lastname: Hedner
authors.affiliation: b Department of Cardiology , University of Oslo, Ullevaal Hospital , Oslo , Norway ;
authors.forename: Sverre E
authors.initials: SE
authors.lastname: Kjeldsen
authors.affiliation: c Department of Hypertension and Diabetology , Medical University of Gdansk , Gdansk , Poland ;
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Narkiewicz
authors.affiliation: d Vascular Biology and Hypertension Program, University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Oparil
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D004338:Drug Combinations; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D040242:Risk Reduction Behavior; D055502:Secondary Prevention
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004338:Drug Combinations; D005343:Fibrinolytic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin